公开(公告)号：US11773082B2

公开(公告)日：2023-10-03

申请号：US17235846

申请日：2021-04-20

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

CPC classification number: C07D403/12 ,  A61P35/00 ,  C07D413/12 ,  C07B2200/07

Abstract: This invention relates to compounds of Formula (I)






and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20170197939A1

公开(公告)日：2017-07-13

申请号：US15300440

申请日：2015-04-01

Applicant: PFIZER INC.

Inventor： Sharanjeet Kaur Bagal ,  Jingrong Jean Cui ,  Samantha Elizabeth Greasley ,  Elizabeth Ann Lunney ,  Indrawan James McAlpine ,  Asako Nagata ,  Sacha Ninkovic ,  Kiyoyuki Omoto ,  Sarah Elizabeth Skerratt ,  Robert Ian Storer ,  Joseph Scott Warmus

IPC: C07D401/14 ,  A61K31/4439 ,  C07D401/12

CPC classification number: C07D401/14 ,  A61K31/4439 ,  C07D401/12

Abstract: The present invention relates to compounds of Formula I and their prodrugs and pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.

公开(公告)号：US09328096B2

公开(公告)日：2016-05-03

申请号：US14705272

申请日：2015-05-06

Applicant: PFIZER INC

Inventor： Sharanjeet Kaur Bagal ,  Jingrong Jean Cui ,  Samantha Elizabeth Greasley ,  Elizabeth Ann Lunney ,  Indrawan James McAlpine ,  Asako Nagata ,  Sacha Ninkovic ,  Kiyoyuki Omoto ,  Sarah Elizabeth Skerratt ,  Robert Ian Storer ,  Joseph Scott Warmus

IPC: A61P35/00 ,  C07D413/14 ,  A61P29/00 ,  C07D405/14 ,  A61K31/4439 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D401/14 ,  C07D401/12 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.

Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐，其中取代基如本文所述，及其在药物中的用途，特别是作为TrkA拮抗剂。

公开(公告)号：US20220089580A1

公开(公告)日：2022-03-24

申请号：US17544303

申请日：2021-12-07

Applicant: Pfizer Inc.

Inventor： Ping Chen ,  Sujin Cho-Schultz ,  Judith Gail Deal ,  Gary Michael Gallego ,  Mehran Jalaie ,  Robert Steven Kania ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Suvi Tuula Marjukka Orr ,  Cynthia Louise Palmer

IPC: C07D407/14 ,  C07D401/14 ,  C07D487/04 ,  C07D498/04

Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

公开(公告)号：US20180044344A1

公开(公告)日：2018-02-15

申请号：US15664265

申请日：2017-07-31

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Ping Chen ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Mehran Jalaie ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Martha Alicia Ornelas ,  Cynthia Louise Palmer ,  Eugene Yuanjin Rui

IPC: C07D487/04 ,  C07D401/14

CPC classification number: C07D487/04 ,  C07D401/14 ,  C07D471/04

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US09593097B2

公开(公告)日：2017-03-14

申请号：US14968405

申请日：2015-12-14

Applicant: Pfizer Inc.

Inventor： Ted William Johnson ,  Paul Francis Richardson ,  Michael Raymond Collins ,  Daniel Tyler Richter ,  Benjamin Joseph Burke ,  Sacha Ninkovic ,  Ketan Satish Gajiwala ,  Maria Angelica Linton ,  Phuong Thi Quy Le ,  Jacqui Elizabeth Hoffman

IPC: C07D401/14 ,  C07D403/14 ,  A61K31/53 ,  A61K31/506 ,  A61K31/4523 ,  A61P35/00 ,  C07D405/14 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D401/14 ,  A61K31/4523 ,  A61K31/506 ,  A61K31/53 ,  C07D403/14 ,  C07D405/14 ,  C07D471/04 ,  C07D487/04

Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Abstract translation: 通式（I）的化合物：这些化合物的制备方法，含有这些化合物的组合物，以及这些化合物的用途。

公开(公告)号：US20160176850A1

公开(公告)日：2016-06-23

申请号：US14968405

申请日：2015-12-14

Applicant: Pfizer Inc.

Inventor： Ted William Johnson ,  Paul Francis Richardson ,  Michael Raymond Collins ,  Daniel Tyler Richter ,  Benjamin Joseph Burke ,  Sacha Ninkovic ,  Ketan Satish Gajiwala ,  Maria Angelica Linton ,  Phuong Thi Quy Le ,  Jacqui Elizabeth Hoffman

IPC: C07D401/14 ,  C07D471/04 ,  C07D487/04 ,  C07D405/14

CPC classification number: C07D401/14 ,  A61K31/4523 ,  A61K31/506 ,  A61K31/53 ,  C07D403/14 ,  C07D405/14 ,  C07D471/04 ,  C07D487/04

Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Abstract translation: 通式（I）的化合物：这些化合物的制备方法，含有这些化合物的组合物，以及这些化合物的用途。

公开(公告)号：US09040515B2

公开(公告)日：2015-05-26

申请号：US14132567

申请日：2013-12-18

Applicant: Pfizer Inc.

Inventor： Martin Paul Edwards ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Indrawan James McAlpine ,  Sacha Ninkovic ,  Eugene Yuanjin Rui ,  Scott Channing Sutton ,  John Howard Tatlock ,  Martin James Wythes ,  Luke Raymond Zehnder

IPC: C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract translation: 本发明涉及通式（I）的化合物，其中R1，R2，U，V，L，M，R5，m，X，Y和Z如本文所定义，及其药学上可接受的盐， 这些化合物和盐，以及使用这些化合物，盐和组合物用于治疗异常细胞生长（包括癌症）的方法。

公开(公告)号：US11718603B2

公开(公告)日：2023-08-08

申请号：US17235836

申请日：2021-04-20

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

CPC classification number: C07D403/12 ,  A61P35/00 ,  C07D413/12 ,  C07B2200/07

Abstract: This invention relates to compounds of Formula (I)




and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20220324872A1

公开(公告)日：2022-10-13

申请号：US17841138

申请日：2022-06-15

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Ping Chen ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Mehran Jalaie ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Martha Alicia Ornelas ,  Cynthia Louise Palmer ,  Eugene Yuanjin Rui

IPC: C07D487/04 ,  C07D471/04 ,  C07D401/14

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.